Logo

UFPT

UFP Technologies, Inc.

UFPT

UFP Technologies, Inc. • NASDAQ
$226.69 ▲ 0.90% (+2.02)
Market Cap $1.75 B
52w High $327.68
52w Low $178.26
Dividend Yield 0%
P/E 26.33
Volume 36.31K
Outstanding Shares 7.71M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $154.558M ▲ $19.368M ▲ $16.383M ▼ 10.6% ▼ $2.12 ▼ $28.176M ▼
Q2-2025 $151.176M ▲ $19.214M ▲ $17.18M ▼ 11.364% ▼ $2.23 ▼ $29.016M ▲
Q1-2025 $148.148M ▲ $19.025M ▼ $17.184M ▲ 11.599% ▲ $2.24 ▲ $27.724M ▲
Q4-2024 $144.07M ▼ $19.798M ▲ $16.375M ▲ 11.366% ▲ $2.13 $27.134M ▼
Q3-2024 $145.165M $16.759M $16.361M 11.271% $2.13 $28.721M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $18.226M ▲ $652.821M ▲ $248.908M ▼ $403.913M ▲
Q2-2025 $14.892M ▲ $634.659M ▼ $249.168M ▼ $385.491M ▲
Q1-2025 $14.028M ▲ $642.642M ▲ $281.968M ▼ $360.674M ▲
Q4-2024 $13.45M ▼ $628.995M ▼ $286.235M ▼ $342.76M ▲
Q3-2024 $16.356M $638.508M $309.362M $329.146M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $16.383M ▼ $0 ▼ $0 ▲ $0 ▲ $3.334M ▲ $0 ▼
Q2-2025 $17.18M ▼ $25.331M ▲ $-5.65M ▼ $-19.083M ▼ $864K ▲ $22.474M ▲
Q1-2025 $17.184M ▲ $13.81M ▼ $-2.817M ▲ $-10.698M ▲ $578K ▲ $10.993M ▼
Q4-2024 $16.375M ▲ $24.424M ▲ $-3.884M ▲ $-22.717M ▼ $-2.906M ▼ $21.417M ▲
Q3-2024 $16.361M $19.801M $-197.167M $176.783M $-372K $17.655M

Revenue by Products

Product Q1-2014Q2-2014Q2-2025Q3-2025
Engineering and Development
Engineering and Development
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$150.00M ▲$150.00M ▲
Tooling and Machinery
Tooling and Machinery
 $0 ▲$0 ▲$0 ▲$0 ▲
Component Products
Component Products
 $20.00M ▲$20.00M ▲$0 ▼$0 ▲
Engineered Packaging
Engineered Packaging
 $10.00M ▲$10.00M ▲$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Over the past five years, UFP Technologies has shown very strong growth in both sales and profits. Revenue has climbed steadily each year, and profits have grown even faster than sales, which points to healthier pricing power and better operating efficiency. Profit margins at every level – gross, operating, and net – have expanded meaningfully, suggesting the business is scaling well and managing costs effectively. Earnings per share have increased several times over this period, reflecting both higher profitability and good cost discipline. Overall, the income statement tells the story of a company moving from a smaller niche player toward a more scaled, highly profitable MedTech supplier.

Balance Sheet

Balance Sheet The balance sheet has expanded significantly, with total assets and shareholders’ equity both rising each year, which is consistent with a growing, reinvesting business. The company has taken on more debt recently, likely tied to acquisitions or capacity expansion, so leverage is notably higher now than a few years ago but still appears supported by the enlarged asset and equity base. Cash levels are modest, which keeps the financial profile more efficient but leaves less of a buffer for shocks. In short, the balance sheet shows a stronger, larger company than five years ago, but with more reliance on borrowed money and therefore a greater need for continued steady performance and cash generation.

Cash Flow

Cash Flow Cash flow from operations has grown meaningfully over the period, generally tracking the rise in earnings, which indicates that profits are largely backed by real cash, not accounting adjustments. After funding capital spending, free cash flow has stayed positive most years and has improved as the business scaled, even though the company has continued to invest in facilities and equipment. Capital spending has been relatively steady and manageable, suggesting disciplined investment rather than overly aggressive expansion. The overall picture is of a business that not only grows and reports higher profits but also converts a solid portion of those profits into cash that can support debt, acquisitions, and future growth initiatives.

Competitive Edge

Competitive Edge UFP Technologies operates in specialized medical components and packaging, where deep materials expertise, regulatory know‑how, and tight integration with customers matter more than sheer size. Its role as a custom, one‑stop solutions provider makes it closely embedded in customers’ product design and manufacturing processes, which tends to create long, sticky relationships and high switching costs. The focus on regulated medical and MedTech markets raises barriers to entry for new competitors, as customers value reliability, quality certifications, and proven regulatory compliance. Strategic acquisitions have expanded its capabilities into high‑value niches like robotic surgery and advanced medical packaging, strengthening its position as a key partner to leading medical device companies rather than a simple commodity supplier. The key risks are concentration in healthcare end‑markets, ongoing pressure to meet very high quality standards, and the need to keep innovating to avoid being displaced by lower‑cost or more advanced rivals.

Innovation and R&D

Innovation and R&D Innovation at UFP Technologies is less about a single blockbuster technology and more about continuous, customer‑driven problem solving in materials and manufacturing. The company combines expertise in foams, films, plastics, and composites with advanced processes like compression molding, thermoforming, and cleanroom assembly, enabling highly customized solutions for demanding medical applications. It has developed branded products and systems in areas such as sterile barrier packaging, bioprocess container protection, infection prevention, and securement of medical devices, which help differentiate it beyond simple contract manufacturing. A major future growth vector is its work in robotic‑assisted surgery and safe patient handling, where it already serves multiple programs and has a visible development pipeline. Ongoing patent activity and targeted acquisitions reinforce its innovation engine, though it must continue investing in R&D and close collaborations with customers to stay ahead of regulatory changes and competing technologies.

Summary

Overall, UFP Technologies looks like a niche MedTech supplier that has successfully scaled up: revenues and profits have grown strongly, margins have widened, and cash generation has improved. Its balance sheet has become larger and stronger in equity terms, but also more leveraged, reflecting a shift toward using debt to fund growth and acquisitions, which adds some financial risk and heightens the importance of sustaining cash flow. The company’s competitive edge rests on deep materials science know‑how, regulatory credibility, customized engineering, and close integration into customers’ product development cycles, particularly in attractive areas like robotic surgery and infection prevention. Key opportunities lie in expanding within these high‑growth medical segments and leveraging its one‑stop solution model, while key risks include heavier dependence on a few specialized healthcare markets, tight quality and regulatory requirements, and the burden of higher debt if growth were to slow. The combined financial and strategic picture is of a specialized, innovation‑driven MedTech partner that has transitioned into a higher‑scale, higher‑margin phase, with both meaningful upside potential and a need for disciplined execution to manage its expanded footprint and obligations.

NEWS

November 25, 2025 · 4:10 PM UTC

UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 37th Annual Healthcare Conference

Read more

November 7, 2025 · 7:00 AM UTC

Introducing BRAWN™ — Structural Solutions for Stronger Factory-Built Products

Read more

November 3, 2025 · 4:08 PM UTC

UFP Technologies Announces Strong Q3 2025 Results

Read more

October 29, 2025 · 4:10 PM UTC

UFP Industries Announces Third Quarter 2025 Results

Read more

October 29, 2025 · 9:00 AM UTC

UFP Technologies to Report Third Quarter 2025 Financial Results on November 3, 2025

Read more